AbbVie makes immunology and aesthetics injectables like Skyrizi, Rinvoq, and Botox that patients take repeatedly for years once they start, collecting a recurring payment split between insurers, Medicare, and patients every time a prescription is refilled.
How AbbVie makes money
AbbVie develops immunology and aesthetics injectables—drugs like Skyrizi, Rinvoq, and Botox—that patients take repeatedly for years once they start, then collects payment every month a prescription is refilled. It manufactures the drugs itself and sells through a small number of wholesalers who reach hospitals and pharmacies.
Immunology, aesthetics, neuroscience
concentrated here
for chronic conditions
Simplified. The actual bill is split three ways—insurers, government (Medicare), and patient copays. Source: 10-K FY2025, p.82.
Where the revenue comes from
Revenue by therapeutic area — FY2025 (worldwide)
AbbVie runs as a single global segment with no formal business-unit breakout. Source: 10-K FY2025, p.40.
Source: 10-K FY2025, p.98 (Note 16).
Customers and competitors
AbbVie sells through a small number of U.S. wholesalers who account for essentially all domestic distribution—three wholesalers represent 84% of receivables, though their identities aren't disclosed.
- Johnson & Johnson — competes directly with Skyrizi in psoriasis and ulcerative colitis via Stelara and Tremfya.
- Eli Lilly — competes with Rinvoq and Skyrizi in autoimmune disease prescriptions via Taltz and Omvoh.
- Merz and Ipsen — challenge Botox in both therapeutic and cosmetic markets with Xeomin and Dysport, respectively.
Source: 10-K FY2025, p.82.
The metric that matters most in this sector
AbbVie's largest product, Humira, hit a patent cliff in 2023 when U.S. biosimilars entered the market. Whether follow-on drugs Skyrizi and Rinvoq have actually replaced that lost revenue is the single clearest read on whether this company survived its biggest risk.
Humira vs. Skyrizi+Rinvoq combined revenue
| Year | Humira | Skyrizi + Rinvoq | Total immunology |
|---|---|---|---|
| 2021 | $20.69B | $4.59B | $25.28B |
| 2022 | $21.24B | $7.69B | $28.92B |
| 2023 | $14.40B | $11.73B | $26.14B |
| 2024 | $8.99B | $17.69B | $26.68B |
| 2025 | $4.54B | $25.87B | $30.41B |
Source: 10-K FY2025, p.40; 10-K FY2022, p.42 (2021–2022 figures).
Source: 10-K FY2025, p.14.
Leadership and ownership
CEO Robert A. Michael took over in 2024 and added the board chair role in July 2025. He isn't the founder; he joined Abbott in 1993 and served as AbbVie's CFO from 2018 to 2022 before becoming CEO — a finance-background executive rather than an operations one. Officers and directors together hold under 1% of shares; the largest holders are passive index funds Vanguard (10.2%) and BlackRock (8.5%).
Source: 10-K FY2025, p.30; DEF 14A 2026, p.29.
Capital returns
AbbVie raised its quarterly dividend from $1.64 to $1.73 per share starting with the February 2026 payment ($6.92 annualized). Buybacks have shrunk for three straight years—$1.97B in 2023, $1.71B in 2024, and just $0.98B in 2025—while diluted weighted-average shares outstanding actually rose slightly over the same period, from 1.769B to 1.773B, as new shares issued for employee stock compensation offset the repurchases. In other words, the buyback program isn't currently defending against share dilution.
Source: 10-K FY2025, p.30, 52, 55.
How this company could fail
- Direct U.S. government price-setting (IRA) — under the Inflation Reduction Act, the government now directly negotiates Medicare prices for a growing list of AbbVie drugs: Imbruvica (starting 2026), Vraylar and Linzess (2027), and Botox (2028) — meaning even patent-protected drugs can face government-mandated price cuts.
- The patent cliff repeats — Skyrizi and Rinvoq, now nearly half of total revenue, face U.S. composition-of-matter patent expiration in 2033 (2037 for Rinvoq). The concerns that hit Humira will resurface as those dates approach.
- Concentration in a few wholesalers and pharmacy benefit managers — 84% of U.S. receivables run through three wholesalers, and PBMs control formulary placement. AbbVie has little negotiating leverage if terms turn unfavorable.
Source: 10-K FY2025, p.15–16 (IRA), p.14 (patents), p.82 (wholesaler concentration).
Five-year financials
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | 56,197 | 58,054 | 54,318 | 56,334 | 61,160 |
| YoY growth | — | +3.3% | -6.4% | +3.7% | +8.6% |
| Operating income | 17,924 | 18,117 | 12,757 | 9,137 | 15,075 |
| Free cash flow | 21,990 | 24,248 | 22,062 | 17,832 | 17,816 |
| Total debt | 76,684 | 63,271 | 59,385 | 67,144 | 67,496 |
Sources: 10-K FY2025, p.51 (income), p.55 (cash flow), p.53 (balance sheet); 10-K FY2022, p.49, 51 (2021–2022 figures). FCF = operating cash flow − capex.
What we still don't know
- The exact identities and contract terms of the three U.S. wholesalers handling 84% of receivables aren't disclosed in the filing.
- Whether the 2023–2024 earnings volatility reflects only acquisition-accounting effects or some underlying business slowdown can't be fully separated without reviewing each acquisition's amortization schedule individually.
- The success probability of AbbVie's late-stage pipeline meant to fill the 2033–2037 patent gap isn't addressed by this filing alone and requires checking recent earnings calls and pipeline updates.
Frequently asked questions
What does AbbVie do?
AbbVie develops and manufactures immunology, neuroscience, oncology, and aesthetics drugs — including Skyrizi, Rinvoq, and Botox — that patients take repeatedly for chronic conditions, selling through a small number of U.S. wholesalers.
How did AbbVie replace Humira's lost revenue?
After Humira faced U.S. biosimilar competition starting in 2023, follow-on drugs Skyrizi and Rinvoq grew fast enough that their combined revenue overtook Humira's peak by 2024, and total immunology revenue hit a record in 2025.
What is AbbVie's market cap?
As of this article's data (Sept. 25, 2026 close), AbbVie traded at $264.34 per share, for a market cap of roughly $468.1 billion.